Rivaroxaban FDA review of ROCKET AF data

WikiDoc Resources for Rivaroxaban FDA review of ROCKET AF data
Articles
Most recent articles on Rivaroxaban FDA review of ROCKET AF data Most cited articles on Rivaroxaban FDA review of ROCKET AF data Review articles on Rivaroxaban FDA review of ROCKET AF data Articles on Rivaroxaban FDA review of ROCKET AF data in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Rivaroxaban FDA review of ROCKET AF data Images of Rivaroxaban FDA review of ROCKET AF data Photos of Rivaroxaban FDA review of ROCKET AF data Podcasts & MP3s on Rivaroxaban FDA review of ROCKET AF data Videos on Rivaroxaban FDA review of ROCKET AF data
Evidence Based Medicine
Cochrane Collaboration on Rivaroxaban FDA review of ROCKET AF data Bandolier on Rivaroxaban FDA review of ROCKET AF data TRIP on Rivaroxaban FDA review of ROCKET AF data
Clinical Trials
Ongoing Trials on Rivaroxaban FDA review of ROCKET AF data at Clinical Trials.gov Trial results on Rivaroxaban FDA review of ROCKET AF data Clinical Trials on Rivaroxaban FDA review of ROCKET AF data at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Rivaroxaban FDA review of ROCKET AF data NICE Guidance on Rivaroxaban FDA review of ROCKET AF data NHS PRODIGY Guidance FDA on Rivaroxaban FDA review of ROCKET AF data CDC on Rivaroxaban FDA review of ROCKET AF data
Books
Books on Rivaroxaban FDA review of ROCKET AF data
News
Rivaroxaban FDA review of ROCKET AF data in the news Be alerted to news on Rivaroxaban FDA review of ROCKET AF data News trends on Rivaroxaban FDA review of ROCKET AF data
Commentary
Blogs on Rivaroxaban FDA review of ROCKET AF data
Definitions
Definitions of Rivaroxaban FDA review of ROCKET AF data
Patient Resources / Community
Patient resources on Rivaroxaban FDA review of ROCKET AF data Discussion groups on Rivaroxaban FDA review of ROCKET AF data Patient Handouts on Rivaroxaban FDA review of ROCKET AF data Directions to Hospitals Treating Rivaroxaban FDA review of ROCKET AF data Risk calculators and risk factors for Rivaroxaban FDA review of ROCKET AF data
Healthcare Provider Resources
Symptoms of Rivaroxaban FDA review of ROCKET AF data Causes & Risk Factors for Rivaroxaban FDA review of ROCKET AF data Diagnostic studies for Rivaroxaban FDA review of ROCKET AF data Treatment of Rivaroxaban FDA review of ROCKET AF data
Continuing Medical Education (CME)
CME Programs on Rivaroxaban FDA review of ROCKET AF data
International
Rivaroxaban FDA review of ROCKET AF data en Espanol Rivaroxaban FDA review of ROCKET AF data en Francais
Business
Rivaroxaban FDA review of ROCKET AF data in the Marketplace Patents on Rivaroxaban FDA review of ROCKET AF data
Experimental / Informatics
List of terms related to Rivaroxaban FDA review of ROCKET AF data

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The FDA conducted an advisory committee review regarding the approvability of rivaroxaban for reduction of stroke and systemic embolization in patients with non-valvular atrial fibrillation on September 8th, 2011.

Non-Inferiority Margin

An upper bound of the 95% CI of the hazard ratio was set at 1.38 by the FDA to establish non-inferiority. In no subgroup did the comparison come near the non-inferiority margin, and non-inferiority was clearly observed in all treatment subgroups and in all forms of analysis.

Primary Efficacy Endpoint

The primary efficacy endpoint was stroke and systemic embolization. The efficacy in the trial was driven by a reduction in hemorrhagic stroke and systemic embolization.

Secondary Efficacy Endpoints

There were fewer non-fatal myocardial infarctions in the Rivaroxaban group.

Safety Endpoint(s)

There were more major bleeding events in the rivaroxaban group, however, the risk of fatal bleeds (H.R.=0.61) and hemorrhagic strokes was reduced in the rivaroxaban group.

Cross Trial Comparisons

Dr. Califf emphasized that cross trial comparisons are inappropriate given the variation in design and patient risk.

Method of Transition at the End of the Trial

• In the rivaroxaban arm, the coumadin was started at a maintenance dose rather than using a loading dose
• There was no overlap with blinded study drug and coumading
• No INR was checked for three days
• Heparin bridging rarely used

IDMC indicated that there was no problem with the transition method. At the time the IDMC looked, there were more events in the warfarin arm. The excess number of events in the riva arm was due to an INR under 2 in the riva patients until they achieved anticoagulation. Following rug discontinuation there was a: 6.4% event rate per year in the rivaroxaban arm which is consistent with the rate in patients who are not anticoagulated 1.7 event rate per year in the coumadin arm consistent with effective coumadin therapy The efficacy of heparin bridging has not been established In the RELY trial, patients were rolled over into the RELIABLE study, and there was often not the opportunity to evaluate the patients for rebound. With drug discontinuation during the trial rather than at the end of the trial, there was no excess events.

Time in Therapeutic Range

Dr. Califf argued that:

• TTR is not a surrogate for anticoagulation risk benefit balance.
• TTR is associated with regional variations. The TTR in the US was 64%, and the treatment benefit in the US was greater than in countries with poor TTR such as in Eastern Europe.
• TTR has no effect on the benefit of a novel anticoagulant over coumadin. RELY, ARISTOTLE and ROCKET AF all showed no interaction between center TTR and the benefit of a novel anticoagulant over coumadin.